Soligenix regains oral BDP rights from Sigma-Tau

Soligenix regained the rights to market an oral formulation of beclomethasone dipropionate in Europe and North America after amending a collaboration deal with Sigma-Tau Pharmaceuticals. Beclomethasone dipropionate is a topically active corticosteroid being developed for Crohn's disease in children, gastrointestinal graft-versus-host disease and acute radiation enteritis.

View Full Article in:

Proactive Investors · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA